Sort
64,565 grants matching “drug discovery”
Scalable Synthesis and New Bond Disconnections
$1,152,113Phil S Baran · Scripps Research Institute, The · R35 · FY2017 · GM
Scalable Synthesis and New Bond Disconnections
$1,152,113Phil S Baran · Scripps Research Institute, The · R35 · FY2018 · GM
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
$1,151,963Richard Joseph Johnson · Colorado Research Partners, Llc · U01 · FY2023 · AA
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)
$1,151,953Larry Zeitlin · Mapp Biopharmaceutical, Inc. · U01 · FY2010 · AI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,151,780Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2023 · AI
Oral Delivery Vehicles for RNAi Therapies
$1,150,827Michael P Czech · Univ Of Massachusetts Med Sch Worcester · R01 · FY2013 · DK
SRI TO 13 - CONTINUOUS RODENT AND NON-RODENT PHARMACOKINETIC ASSESSMENTS
$1,150,694Carol Green · Sri International · N01 · FY2023 · DA
Structures of Mtb proteins conferring susceptibility to known Mtb inhibitors
$1,150,586James C Sacchettini · Texas A&M University · U01 · FY2013 · GM
Novel small-molecule therapies for CF
$1,150,450Alan S Verkman · University Of California, San Francisco · P30 · FY2015 · DK
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
$1,150,319Shawn Hingtgen · Univ Of North Carolina Chapel Hill · U01 · FY2022 · TR
Comparative Mammalian Genomics
$1,150,252Elaine Ostrander · National Human Genome Research Institute · ZIA · FY2017 · HG
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$1,149,999Terry L Bowlin · Microbiotix, Inc · U01 · FY2009 · AI
Biomedical Simulations Resource (BMSR)
$1,149,858David Z D'argenio · University Of Southern California · P41 · FY2010 · EB
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION
$1,149,158Steven Carl George · University Of California At Davis · UG3 · FY2017 · HL
Accelerated discovery of methylation targeted therapeutic development
$1,148,788Zu-Wen Sun · Epicypher, Inc. · R44 · FY2018 · CA
Functional and Pharmacological Significance of Receptor Heteromers in the CNS
$1,148,752Sergi Ferre · National Institute On Drug Abuse · ZIA · FY2011 · DA
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD
$1,148,751Samuel V Alworth · Acurastem, Inc. · R44 · FY2020 · NS
Regulation of Hormone Receptors and Gonadal Genes
$1,148,546Maria Dufau · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2022 · HD
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,148,492Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2015 · EY
Molecular Studies of Malformations
$1,148,479Leslie Biesecker · National Human Genome Research Institute · ZIA · FY2017 · HG
eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
$1,148,465Alexander A Shishkin · Eclipse Bioinnovations Inc · R44 · FY2025 · GM
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Center
$1,148,169Mariana C Stern · University Of Southern California · U54 · FY2025 · CA
MPS Qualification Section
$1,148,044Mark E Schurdak · University Of Pittsburgh At Pittsburgh · U2C · FY2024 · TR
A functional evolutionary genetic approach to combat viral infection
$1,148,000John W. Schoggins · Ut Southwestern Medical Center · DP1 · FY2024 · AI
A functional evolutionary genetic approach to combat viral infection
$1,148,000John W. Schoggins · Ut Southwestern Medical Center · DP1 · FY2023 · AI